Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.
OBJECTIVE
To evaluate the efficacy of trimetazidine (TMZ) in the prevention of contrast-induced nephropathy (CIN) in patients with high serum creatinine levels undergoing coronary angiography/angioplasty.


METHODS
TMZ (20 mg thrice daily) was administered orally for 72 h starting 48 h before the procedure. All patients were given intravenous saline (0.9%) at a rate of 1 ml/kg of body weight per hour for 24 h starting 12 h beforehand. Serum creatinine levels were measured before the procedure, 48 h and 7 days after the procedure. Increase in serum creatinine level exceeding 0.5 mg/day or one quarter of the basal value is considered as CIN. Venous blood samples for serum total antioxidant capacity (TAC) measurement were drawn before and after coronary angiography.


RESULTS
Basal serum creatinine levels and TAC were similar in TMZ and control groups. Serum creatinine levels in the control group increased significantly 2 days after the procedure, and returned to the baseline values on the seventh day. However, it did not change significantly on the second day, and even significantly decreased on the seventh day in the TMZ group. CIN developed in 2.5% (1/40) of patients in the TMZ group and in 16.6% (7/42) of patients in the control group (p<0.05). TAC values were not different between treatment groups.


CONCLUSIONS
TMZ along with isotonic saline infusion is more effective than isotonic saline alone in reducing the risk of CIN in patients with pre-existing renal dysfunction.
Onbasili
Alper O
AO
Department of Cardiology, School of Medicine, Adnan Menderes University, Aydin, Turkey. aonbasili@adu.edu.tr
Yeniceriglu
Yavuz
Y
Agaoglu
Pinar
P
Karul
Aslihan
A
Tekten
Tarkan
T
Akar
Harun
H
Discigil
Guzel
G
D000284:Administration, Oral; D015906:Angioplasty, Balloon, Coronary; D006328:Cardiac Catheterization; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography; D003404:Creatinine / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007472:Iohexol / Q000009:adverse effects / Q000031:analogs & derivatives*; D007552:Isotonic Solutions; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011292:Premedication; D011446:Prospective Studies; D051436:Renal Insufficiency, Chronic / Q000097:blood; D012965:Sodium Chloride; D014292:Trimetazidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D003287:Contrast Media; D007552:Isotonic Solutions; D014665:Vasodilator Agents; D007472:Iohexol; D012965:Sodium Chloride; C038192:iopromide; D003404:Creatinine; D014292:Trimetazidine